0.20
+0.0054(+2.77%)
Currency In USD
| Previous Close | 0.19 |
| Open | 0.2 |
| Day High | 0.2 |
| Day Low | 0.19 |
| 52-Week High | 3.43 |
| 52-Week Low | 0.16 |
| Volume | 372,236 |
| Average Volume | 398,874 |
| Market Cap | 4.3M |
| PE | -0.12 |
| EPS | -1.6 |
| Moving Average 50 Days | 0.21 |
| Moving Average 200 Days | 0.42 |
| Change | 0.01 |
If you invested $1000 in Oragenics, Inc. (OGEN) 10 years ago, it would be worth $0.43 as of May 19, 2025 at a share price of $0.2. Whereas If you bought $1000 worth of Oragenics, Inc. (OGEN) shares 5 years ago, it would be worth $5.13 as of May 19, 2025 at a share price of $0.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
GlobeNewswire Inc.
May 13, 2025 12:30 PM GMT
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that it has received approval from the Hum
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
GlobeNewswire Inc.
May 12, 2025 12:30 PM GMT
Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&ASARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on deve
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
GlobeNewswire Inc.
Apr 23, 2025 12:30 PM GMT
SARASOTA, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing novel intranasal therapies for concussion and brain-related conditions, today announced its participation in the 15th Annual